ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 4987-4998

  Wang, Hongtao ^a   Qi, Zhi ^b   Guo, Angi ^b   Mao, Qinchao ^a   Lu, Hong ^b   An, Xiuli ^b   Xia, Chenglai ^a   Li, Xiaojuan ^a   Debnath, Asim K ^b   Wu, Shuguang ^a   Liu, Shuwen ^a   Jiang, Shibo ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADS J1; ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; PROTEIN IQN17; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CELL FUSION ASSAY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MEMBRANE FUSION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; TIME OF ADDITION ASSAY; VIRUS ENTRY;

ANTI-HIV AGENTS; ANTIGENS, CD34; ANTIGENS, CD4; CELL LINE, TUMOR; CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NAPHTHALENESULFONATES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CXCR4; TRIAZINES; VIRUS REPLICATION;

EID: 71249111434     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00670-09     Document Type: Article

References (56)

1. Armand-Ugon, M., I. Clotet-Codina, C. Tintori, F. Manetti, B. Clotet, M. Botta, and J. A. Este. 2005. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 343:141-149. (Pubitemid 41572240)
2. Baldwin, C. E., R. W. Sanders, Y. Deng, S. Jurriaans, J. M. Lange, M. Lu, and B. Berkhout. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428-12437. (Pubitemid 39458761)
3. Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11:3-16.
4. Chan, D. C., C. T. Chutkowski, and P. S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95:15613-15617.
5. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
6. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
7. De, C., S. Grothe, R. Lortie, M. T. Debanne, and M. O'Connor-McCourt. 2000. Real-time kinetic studies on the interaction of transforming growth factor with the epidermal growth factor receptor extracellular domain reveal a conformational change model. Biochemistry 39:9466-9476.
8. Debnath, A. K., L. Radigan, and S. Jiang. 1999. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42:3203-3209.
9. de Rosny, E., R. Vassell, P. T. Wingfield, C. T. Wild, and C. D. Weiss. 2001. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J. Virol. 75: 8859-8863.
10. Dezube, B. J., T. A. Dahl, T. K. Wong, B. Chapman, M. Ono, N. Yamaguchi, S. D. Gillies, L. B. Chen, and C. S. Crumpacker. 2000. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study. J. Infect. Dis. 182:607-610.
11. Dwyer, J. J., K. L. Wilson, D. K. Davison, S. A. Freel, J. E. Seedorff, S. A. Wring, N. A. Tvermoes, T. J. Matthews, M. L. Greenberg, and M. K. Delmedico. 2007. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. USA 104:12772-12777.
12. Eckert, D. M., V. N. Malashkevich, L. H. Hong, P. A. Carr, and P. S. Kim. 1999. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103-115.
13. Esté, J. A., C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R. F. Rando, B. Clotet, J. Desmyter, and E. De Clercq. 1998. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (zintevir). Mol. Pharmacol. 53:340-345.
14. Greenfield, C., I. Hiles, M. D. Waterfield, M. Federwisch, A. Wollmer, T. L. Blundell, and N. McDonald. 1989. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 8:4115-4123. (Pubitemid 20066854)
15. He, Y., S. Liu, W. Jing, H. Lu, D. Cai, D. J. Chin, A. K. Debnath, F. Kirchhoff, and S. Jiang. 2007. Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J. Biol. Chem. 282:25631-25639.
16. He, Y., S. Liu, J. Li, H. Lu, Z. Qi, Z. Liu, A. K. Debnath, and S. Jiang. 2008. Conserved salt-bridge between the N- and C-terminal heptad repeat regions of HIV-1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82:11129-11139.
17. Huang, J. H., Z. Qi, F. Wu, L. Kotula, S. Jiang, and Y. H. Chen. 2008. Interaction of HIV-1 gp41 core with NPF motif in epsin: implication in endocytosis of HIV. J. Biol. Chem. 283:14994-15002.
18. Hunter, E. 1997. gp41, a multifunctional protein involved in HIV entry and pathogenesis, p. III-55-III-73. In B. Korber, B. Hahn, B. Foley, J. W. Mellors, T. Leitner, G. Myers, F. McCutchan, and C. Kuiken (ed.), Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, NM.
19. Jiang, S., and A. K. Debnath. 2000. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. 270: 153-157.
20. Jiang, S., K. Lin, and M. Lu. 1998. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 72:10213-10217.
21. Jiang, S., K. Lin, and A. R. Neurath. 1991. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174:1557-1563.
22. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
23. Jiang, S., K. Lin, L. Zhang, and A. K. Debnath. 1999. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 80:85-96. (Pubitemid 29248906)
24. Jiang, S., H. Lu, S. Liu, Q. Zhao, Y. He, and A. K. Debnath. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:4349-4359.
25. Jiang, S., L. Radigan, and L. Zhang. 2000. A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc. Soc. Photog. Instr. Eng. 3926:212-219.
26. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41- mediated virus entry. Nat. Med. 4:1302-1307.
27. Liu, S., L. Boyer-Chatenet, H. Lu, and S. Jiang. 2003. Rapid and automated fluorescence-linked immunosorbent assay for high throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screen. 8:685-693.
28. Liu, S., and S. Jiang. 2004. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr. Pharm. Des. 10:1827-1843.
29. Liu, S., W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang. 2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282:9612-9620.
30. Liu, S., H. Lu, Y. Xu, S. Wu, and S. Jiang. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280:11259-11273.
31. Liu, S., S. Wu, and S. Jiang. 2007. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 13:143-162.
32. Liu, S., Q. Zhao, and S. Jiang. 2003. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 24:1303-1313. (Pubitemid 38045537)
33. Lu, H., Q. Zhao, Z. Xu, and S. Jiang. 2003. Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. J. Virol. Methods 107:155-161. (Pubitemid 36005500)
34. Lu, L., Y. Zhu, J. Huang, X. Chen, H. Yang, S. Jiang, and Y. H. Chen. 2008. Surface exposure of the HIV-1 Env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 283:16723-16731.
35. Lu, M., S. C. Blacklow, and P. S. Kim. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
36. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
37. Matsuzaki, K., T. Ogino, T. Sunazuka, H. Tanaka, and S. Omura. 1997. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. J. Antibiot. (Tokyo) 50:66-69.
38. McKnight, A., D. Wilkinson, G. Simmons, S. Talbot, L. Picard, M. Ahuja, M. Marsh, J. A. Hoxie, and P. R. Clapham. 1997. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71:1692-1696. (Pubitemid 27030351)
39. Menendez-Arias, L., and J. A. Este. 2004. HIV-resistance to viral entry inhibitors. Curr. Pharm. Des. 10:1845-1860.
40. Mink, M., S. M. Mosier, S. Janumpalli, D. Davison, L. Jin, T. Melby, P. Sista, J. Erickson, D. Lambert, S. A. Stanfield-Oakley, M. Salgo, N. Cammack, T. Matthews, and M. L. Greenberg. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79:12447-12454. (Pubitemid 41346107)
41. Moore, J. P., B. A. Jameson, R. A. Weiss, and Q. J. Sattentau. 1993. The HIV-cell fusion reaction, p. 233-289. In J. Bentz (ed.), Viral fusion mechanisms. CRC Press, Boca Raton, FL.
42. Murakami, T., T. Nakajima, Y. Koyanagi, K. Tachibana, N. Fujii, H. Tamamura, N. Yoshida, M. Waki, A. Matsumoto, O. Yoshie, T. Kishimoto, N. Yamamoto, and T. Nagasawa. 1997. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1389-1393.
43. Peisajovich, S. G., S. A. Gallo, R. Blumenthal, and Y. Shai. 2003. C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion. J. Biol. Chem. 278:21012-21017.
44. Qi, Z., W. Shi, N. Xue, C. Pan, W. Jing, K. Liu, and S. Jiang. 2008. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem. 283:30376-30384.
45. Ray, N., L. A. Blackburn, and R. W. Doms. 2009. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83:2989-2995.
46. Tan, K., J. Liu, J. Wang, S. Shen, and M. Liu. 1997. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94: 12303-12308.
47. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
48. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-428. (Pubitemid 27227210)
49. Welch, B. D., A. P. VanDemark, A. Heroux, C. P. Hill, and M. S. Kay. 2007. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA 104:16828-16833.
50. Wexler-Cohen, Y., B. T. Johnson, A. Puri, R. Blumenthal, and Y. Shai. 2006. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J. Biol. Chem. 281:9005-9010.
51. Wexler-Cohen, Y., and Y. Shai. 2007. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21:3677-3684. (Pubitemid 350075155)
52. Wild, C., T. Oas, C. McDanal, D. Bolognesi, and T. Matthews. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89:10537-10541.
53. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
54. Xu, L., A. Pozniak, A. Wildfire, S. A. Stanfield-Oakley, S. M. Mosier, D. Ratcliffe, J. Workman, A. Joall, R. Myers, E. Smit, P. A. Cane, M. L. Greenberg, and D. Pillay. 2005. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49:1113-1119.
55. Zhao, Q., J. T. Ernst, A. D. Hamilton, A. K. Debnath, and S. Jiang. 2002. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retrovir. 18:989-997.
56. Zhao, Q., L. Ma, S. Jiang, H. Lu, S. Liu, Y. He, N. Strick, N. Neamati, and A. K. Debnath. 2005. Identification of N-phenyl-N′-(2,2,6,6- tetramethyl-piperidin- 4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225.